Alyteserin-2a [A10W, G11k]

General Information


DRACP ID  DRACP02103

Peptide Name   Alyteserin-2a [A10W, G11k]

Sequence  ILGKLLSTAWkLLSNL

Sequence Length  16

UniProt ID  Not available

PubChem CID  Not available

Origin  Synthetic (Derived from Alyteserin-2a)

Type  Synthetic peptide

Classification

  

Active ACP



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
A549 Lung adenocarcinoma Carcinoma LC50=17 μM CellTiter-Glo Luminescent Cell Viability assay 24 h 1

Hemolytic Activity  Human erythrocytes: 50% Hemolysis=21 µM

Normal (non-cancerous) Cytotoxicity  Not available

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer; Antimicrobial; Antifungal



Structure Information


PDB ID  Not available

Predicted Structure  Not available

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Amidation

Other Modification  k=D-Lys

Chiral  Mix



Physicochemical Information


Formula  C78H130N18O19

Absent amino acids  CDEFHMPQRVY

Common amino acids  L

Mass  189175

Pl  9.7

Basic residues  1

Acidic residues  0

Hydrophobic residues  9

Net charge  1

Boman Index  1796

Hydrophobicity  113.13

Aliphatic Index  176.88

Half Life 
  /

Extinction Coefficient cystines  5500

Absorbance 280nm  366.67

Polar residues  5

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 22965637

Title  Transformation of the naturally occurring frog skin peptide, alyteserin-2a into a potent, non-toxic anti-cancer agent

Doi 10.1007/s00726-012-1395-7

Year  2013

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DBAASP ID  DBAASPS_4376

DRACP is developed by Dr.Zheng's team.